PGEN vs ZBIO: stock comparison and AI forecast
Precigen, Inc. (PGEN) and Zenas Biopharma, Inc. (ZBIO) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
PGEN Precigen, Inc.
- Price
- $4.22 +1.7% · 6M
- Market Cap
- $1.51B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
ZBIO Zenas Biopharma, Inc.
- Price
- $25.93 +24.5% · 6M
- Market Cap
- $1.69B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- ZBIO is 1.1 times larger than PGEN by market capitalization ($1.69B against $1.51B).
- Over the last six months ZBIO returned +24.5% and PGEN +1.7%.
- ZBIO carries 2.18 times debt per unit of equity, against 1.53 times for PGEN.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | PGEN | ZBIO |
|---|---|---|
| Market Cap | $1.51B | $1.69B |
| P/B Ratio | 18.03x | 7.96x |
| EPS | $-0.23 | $-10.85 |
| Book Value/Share | $0.23 | $3.26 |
| Revenue/Share | $0.23 | – |
| FCF/Share | $-0.21 | $-3.73 |
Profitability & Margins
| Metric | PGEN | ZBIO |
|---|---|---|
| ROE | – | -255.2% |
| ROA | – | -80.2% |
| ROIC | -30.4% | -86.1% |
| Operating Margin | -65.9% | -4785.5% |
| Net Margin | – | -4925.5% |
| EBT Margin | -241.6% | -4923.1% |
| Tax Rate | -0.1% | -0.1% |
Financial Health
| Metric | PGEN | ZBIO |
|---|---|---|
| Current Ratio | 5.58x | 9.42x |
| Quick Ratio | 4.83x | – |
| D/E Ratio | 1.53x | 2.18x |
| Financial Leverage | 2.53x | 3.18x |
| Interest Coverage | 14.8x | -50.2x |
| Working Capital | $141M | $539M |
Cash Flow
| Metric | PGEN | ZBIO |
|---|---|---|
| Operating Cash Flow | -$73M | -$243M |
| Free Cash Flow | -$74M | -$243M |
| Capital Spending | -$1M | $0.00M |
| FCF/Sales | -88.7% | – |
| CapEx/Sales | 1.3% | – |
Operational Efficiency
| Metric | PGEN | ZBIO |
|---|---|---|
| Asset Turnover | 0.40x | – |
| Receivables Turnover | 0.9x | – |
| Fixed Assets Turnover | 6.3x | – |
| Days Sales Outstanding | 420 days | – |
Income Statement
| Metric | PGEN | ZBIO |
|---|---|---|
| Total Revenue | $84M | – |
| Operating Income | -$55M | -$526M |
| Net Income | – | -$542M |
| R&D Expense | $61M | $238M |
| SG&A Expense | $136M | – |
Dividend & Shareholder Information
| Metric | PGEN | ZBIO |
|---|---|---|
| Shares Outstanding | 358M | 65M |
PGEN vs ZBIO: stock comparison and AI forecast
Which is bigger, PGEN or ZBIO?
ZBIO is 1.1 times larger than PGEN by market capitalization ($1.69B against $1.51B).
Which stock performed better over the last six months, PGEN or ZBIO?
Over the last six months ZBIO returned +24.5% and PGEN +1.7%.
Which one does Intratio's AI model rank higher, PGEN or ZBIO?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.